| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.0 | 0.0 |
| Net income | -4.0 | -4.4 |
| EPS (diluted, $ a share) | $-0.05 | $-0.11 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: TLPH. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Talphera, Inc.: key numbers
- Share price
- $0.8609Close, Nov 16
- Market cap
- $44.7M
- Shares outstanding
- 51.96MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Talphera, Inc.
All →Talphera Financial Results
Talphera reported a Q3 2026 net loss of $4.0 million and ended the quarter with $14.2 million in cash and investments. The company has submitted a briefing document to the FDA requesting to close enrollment for its pivotal NEPHRO CRRT study by year-end 2026, citing that current enrollment provides over 80% statistical power for the primary endpoint.
“We believe nafamostat has the potential to address an important unmet need as a regional anticoagulant for critically ill patients undergoing CRRT. Our updated market research, including physician feedback on nafamostat compared with currently used products, supports its potential adoption in CRRT and an increased peak sales estimate of more than $200 million.”
Vince Angotti, CEO of Talphera
“To date, we have enrolled more than 75% of the planned 70 patients. To support our goal of completing the study this year, we have submitted a briefing document to the FDA seeking feedback on closing enrollment as of December 31, 2026, even if fewer than the targeted 70 patients are enrolled. While the study remains blinded and open for enrollment, we believe the current enrollment is sufficient to support a PMA filing as it has over 80% statistical power for the primary endpoint.”
Vince Angotti, CEO of Talphera